Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Huatai Chenguang Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise located in Nanjing, China, dedicated to the R&D, production, and sales of innovative and high-end generic drugs. The company focuses on major chronic diseases, including cardiovascular, metabolic, and infectious conditions. Its portfolio includes several marketed generic products such as Rosuvastatin and Entecavir, alongside a pipeline of novel small molecule candidates targeting SGLT2 and DPP-4. Huatai Chenguang operates a modern manufacturing facility that complies with national GMP standards, supporting its mission to deliver high-quality healthcare solutions. The company is recognized as a High-tech Enterprise and maintains a strong focus on integrating chemical synthesis with advanced pharmaceutical formulations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 江苏华泰晨光药业.